Completed PHASE4 INTERVENTIONAL 2-arm NCT03948191

99Tc-MDP for Thyroid-Associated Ophthalmopathy

A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.

Sponsor: Dalian University

Conditions Thyroid-Associated Ophthalmopathy

Interventions 99Tc-MDP(99Technetium-Methylenediphosphonate Injection) Methylprednisolone

Updated 4 times since 2019 Last updated: May 13, 2019 Started: Oct 16, 2017 Primary completion: Dec 30, 2018 Completion: Mar 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03948191, this PHASE4 trial focuses on Thyroid-Associated Ophthalmopathy and remains completed. Sponsored by Dalian University, it has been updated 4 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2019 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Oct 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dalian University

Data source: Dalian University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dalian, China